2023 WHO country and area rates, new and relapse cases per 100,000 people.
Tuberculosis incidence is compared across WHO country and area rows in 2023 using new and relapse cases per 100,000 people. The ranking uses the top 10 country and area rates from one WHO Data indicator. Marshall Islands ranked highest at 692 cases per 100,000 people, ahead of Lesotho at 664. The leader was 1.41 times the tenth-ranked Mongolia rate, a 201-case gap per 100,000 people.
| Rank | Entry | Value | Period |
|---|---|---|---|
| 1 | Marshall Islands | 692 | 2023 |
| 2 | Lesotho | 664 | 2023 |
| 3 | Philippines | 643 | 2023 |
| 4 | Myanmar | 558 | 2023 |
| 5 | Central African Republic | 540 | 2023 |
| 6 | Kiribati | 533 | 2023 |
| 7 | Democratic People's Republic of Korea | 513 | 2023 |
| 8 | Gabon | 505 | 2023 |
| 9 | Timor-Leste | 498 | 2023 |
| 10 | Mongolia | 491 | 2023 |
Source 1: World Health Organization Global Health Observatory
Publisher: World Health Organization
Dataset/table: Global Health Observatory
Units: New and relapse TB cases per 100,000 people
Date checked: 2026-05-26
Evidence: Supports the 2023 tuberculosis incidence rate by country and area.
The rate is new and relapse TB cases per 100,000 people. The WHO country/area universe can include areas as well as sovereign states, so the page uses country/area wording.
Uses WHO Data country/area values for 2023. Rows are the 10 highest published incidence rates; the multiple divides rank 1 by rank 10 and the gap subtracts rank 10 from rank 1.
All 10 rows use WHO Data, the same 2023 period and the same cases-per-100,000-people unit.
Keep the visible MarketStats attribution, source line and canonical page link intact. For clean unbranded assets, commercial use or higher-volume reuse, choose one of the licensing tiers below.
* Free branded use is subject to the Terms and requires attribution/canonical-link preservation. MarketStats licenses the graphic presentation and MarketStats-created editorial layer, not the underlying third-party source data. Source attribution and source-provider obligations still apply.
